The more advanced stage did not seem to affect the treatment setting which was similar between cohorts (P = 0.50 for NSCLC, P = 0.72 for SCLC), nor the molecular profile with a similar number of pts with tumors harboring targetable alterations (19% versus 19%) and PD-L1 positivity (64% versus 61%, P = 0.15). This evidence concerns the gene CD274 and small cell lung carcinoma.